A Study to Evaluate Effects on Sleep and Safety of RE03 in PTSD Patients With Sleep Disturbances

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 10, 2025

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2026

Conditions

Posttraumatic Stress Disorder (PTSD)Sleep Disturbances and Insomnia

Interventions

DRUG

RE03

Buccal Dexmedetomidine

DRUG

Placebo

Matching Placebo

Trial Locations (1)

RECRUITING

Human Sleep Pharmacology, University of Zurich, Zurich

All Listed Sponsors

collaborator

University of Zurich

OTHER

lead

Reconnect Labs

INDUSTRY

NCT06685965 - A Study to Evaluate Effects on Sleep and Safety of RE03 in PTSD Patients With Sleep Disturbances | Biotech Hunter | Biotech Hunter